Technology: CAR-T therapy, Cell-based gene therapy, Сancer Diagnostics
Industry: Genomic and Epigenominc Instabillity, Public
Headquarters: Houston, Texas, United States
Founded Date: 2004-07-01
Employees Number: 101-250
Funding Status: IPO
Investors Number: 15
Total Funding: 289575000
Estimated Revenue: Less than $1M
Last Funding Date: 2020-10-29
Last Funding Type: Post-IPO Equity

Visit Website
info@bellicum.com
http://twitter.com/BellicumPharma
Register and Claim Ownership